(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/196217 A1

(51) International Patent Classification:
C07K 16/18 (2006.01) *A61P 25/28* (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/EP2025/057692

(22) International Filing Date:
20 March 2025 (20.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24165076.1 21 March 2024 (21.03.2024) EP

(71) Applicant: **UCB BIOPHARMA SRL** [BE/BE]; Allée de la Recherche 60, 1070 Brussels (BE).

(72) Inventors: **EWEN, Colin**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **GERMANI, Massimiliano**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **BUCHANAN, Timothy John**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(74) Agent: **J A KEMP LLP**; 80 Turnmill Street, London EC1M 5QU (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF TAUOPATHIES WITH TAU-BINDING ANTIBODIES

(57) Abstract: The present invention provides a tau-binding antibody or antigen-binding fragment thereof for use in a method of treating a tauopathy in a human subject in need thereof, wherein the antibody or antigen-binding fragment thereof is administered according to a particular regimen.



Figure 1

WO 2025/196217 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*